Supplementary Figure 1 from A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma

Authors :: Won Young Tak
Chia-Jui Yen
Michael Jeffers
Heiko Krissel
Prabhu Rajagopalan
Christian Kappeler
Wen-Son Hsieh
Miah Hiang Tay
Joong-Won Park
Winnie Yeo
Ronnie T.P. Poon
Kun-Ming Rau
Chiun Hsu
Jung-Hwan Yoon
Cheng-Yao Lin
Hye Jin Choi
Jeong Heo
Ho Yeong Lim
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: Supplementary Figure 1. CONSORT diagram

Tools